Deep vein thrombosis screening: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 2: | Line 2: | ||
There is no clear clinical value for screening, in-spite of identifying patients at increased risk of VTE. The following reason explains | There is no clear clinical value for screening, in-spite of identifying patients at increased risk of VTE. The following reason explains | ||
* The strongest risk factor for VTE recurrence is the prior VTE event itself. | * The strongest risk factor for VTE recurrence is the prior VTE event itself. | ||
* In VTE patients where the cause was unknown, after discontinuation of warfarin irrespective of the presence of inherited thrombophilia, are at high risk of recurrence | * In VTE patients where the cause was unknown, after discontinuation of warfarin irrespective of the presence of inherited thrombophilia, are at high risk of recurrence. | ||
*Anticoagulant prophylaxis is rarely recommended in asymptomatic affected family members outside of high risk situations. | |||
Revision as of 14:35, 24 August 2011
Value of screening
There is no clear clinical value for screening, in-spite of identifying patients at increased risk of VTE. The following reason explains
- The strongest risk factor for VTE recurrence is the prior VTE event itself.
- In VTE patients where the cause was unknown, after discontinuation of warfarin irrespective of the presence of inherited thrombophilia, are at high risk of recurrence.
- Anticoagulant prophylaxis is rarely recommended in asymptomatic affected family members outside of high risk situations.